Why 2018 is a make-or-break year for pharma

 

Next year looks — at least on paper — like an unprecedentedly good setup for the pharmaceutical industry.

 

But behind the scientific breakthroughs, a Food and Drug Administration churning out approvals and drug-price regulation never materializing, the industry appears shockingly fragile.

 

Some of drugmakers’ most profitable products are aging, or simply old — nearly two decades old, in some cases — and staring down new competition.

 

Meanwhile, many big companies’ pipelines, typically a source of new development and the next billion-dollar drugs, are dry.

 

Acquisitions will thus become an integral part of the path forward, industry observers say, especially after a year of underwhelming merger-and-acquisition activity…

 

Read the full article provided by Emma Court here.